Immunome (IMNM) Enterprise Value (2023 - 2025)
Immunome (IMNM) has disclosed Enterprise Value for 3 consecutive years, with -$653.5 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Enterprise Value fell 200.72% year-over-year to -$653.5 million, compared with a TTM value of -$653.5 million through Dec 2025, down 200.72%, and an annual FY2025 reading of -$653.5 million, down 200.72% over the prior year.
- Enterprise Value was -$653.5 million for Q4 2025 at Immunome, down from -$272.6 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$38.4 million in Q2 2023 and bottomed at -$653.5 million in Q4 2025.
- Average Enterprise Value over 3 years is -$239.0 million, with a median of -$254.1 million recorded in 2024.
- The sharpest move saw Enterprise Value plummeted 624.58% in 2024, then increased 3.71% in 2025.
- Year by year, Enterprise Value stood at -$138.1 million in 2023, then tumbled by 57.3% to -$217.3 million in 2024, then plummeted by 200.72% to -$653.5 million in 2025.
- Business Quant data shows Enterprise Value for IMNM at -$653.5 million in Q4 2025, -$272.6 million in Q3 2025, and -$268.0 million in Q2 2025.